ClinConnect ClinConnect Logo
Search / Trial NCT01275300

Biosynthesis of PGD2 in Vivo

Launched by UNIVERSITY OF PENNSYLVANIA · Jan 10, 2011

Trial Information

Current as of July 05, 2025

Completed

Keywords

ClinConnect Summary

The purpose of this study is to look at the roles of various blood cells and their contributions of different prostaglandins. The intention is that by better understanding these prostaglandins and various metabolites, it will provide insights into their roles in the cardiovascular system.

Prostaglandins and metabolites are naturally occurring substances found in the blood and urine which can act as markers which can be quantified and studied as we will be doing in this study. Flushing response to niacin will also be assessed by laser doppler measuring blood flow of the facial skin.

Untran...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • age between 18-70
  • subject must be in good health as based on medical history
  • All subjects must be non-smoking, non-pregnant volunteers
  • Female subjects of child bearing potential must be using a medically acceptable method of contraception throughout the entire study period. All female subjects must consent to a urine pregnancy test at screening and just prior to the start of each treatment period of the study, which must be negative at all time points.
  • Exclusion Criteria:
  • subjects with any medical condition that according to the investigator may interfere with interpretation of the study results, be indicative of an underlying disease state, or compromise the safety of a potential subject.
  • subjects who have received an experimental drug within 30 days prior to the study.
  • subjects who have taken medications at least 10 days prior to the study. Birth Control pills are acceptable and shall not be excluded.
  • Subjects who have taken aspirin or aspirin containing products for at least 10 days prior to the study.
  • Subjects who have taken acetaminophen, NSAIDS, COX-2 inhibitors (OTC or prescription) for at least 10 days prior to the study.
  • Subjects who are currently consuming any type of tobacco product(s).
  • Subjects who consume high doses of antioxidant vitamins daily (vitamin C \> 1000mg, Vitamin E \> 400 IU, Beta Carotene \> 1000IU, Vitamin A \> 5000IU, Selenium \> 200mcg, Folic Acid \> 1mg) for the 2 weeks prior to the start of the study and throughout the study.
  • Subjects who consume alcohol, caffeine or high fat food 24 hours prior to study.

About University Of Pennsylvania

The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.

Locations

Philadelphia, Pennsylvania, United States

Patients applied

0 patients applied

Trial Officials

Wenliang Song, MD

Principal Investigator

University of Pennsylvania

Garret FitzGerald, MD

Study Chair

University of Pennsylvania

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials